You're not ramping. You're making a sensible reasoned argunent and joining dots.
As for the melanoma preclinical, you're correct. Why would RAC try Zantrene with only one PD-1(L) inhibitor? RAC would try Zantrene with all of them, most likely one at a time, but maybe also with more than one at a time
So the next question is when this part of the melanoma preclinical will read out? Sounds complex, need to trial firstly Zantrene, measure tumour response, then the combinations, measure tumour response. I'm guessing roughly Q3 next year.
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-175
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |